Ketamine/Esketamine in the Treatment of Serious and Persistent Depression: Practical Considerations-Presentation Slides

Presentation Slides

Pdf Summary

This document provides a summary of key points from a webinar on the use of ketamine and esketamine in the treatment of serious and persistent depression. The webinar was part of an initiative by the American Psychiatric Association (APA) and the Substance Abuse and Mental Health Services Administration (SAMHSA).<br /><br />The webinar discussed the clinical support system for serious mental illness (CSS-SMI) and provided information on funding for the initiative. It also addressed continuing education credits for physicians and nurses.<br /><br />The presentation included a question and answer session, and the presenter disclosed financial relationships and potential conflicts of interest.<br /><br />The webinar highlighted the history of ketamine's rapid onset of antidepressant effects and its early clinical evidence. It emphasized the need for new antidepressant treatments due to the high prevalence of depression and the limitations of current medications. It also examined the factors influencing the onset of activity and the discovery of ketamine's antidepressant properties.<br /><br />The presentation explored the rationale for using ketamine and discussed its efficacy in various studies. It also discussed the balance between the potential benefits and risks of ketamine treatment, including substance abuse liability.<br /><br />The webinar addressed important questions related to ketamine treatment, including optimal dosing strategies, effectiveness, safety, and moderators of response and adverse effects. It also discussed the relevance of ketamine to drug development and the need to understand the mechanisms of its antidepressant action.<br /><br />The document summarized findings on the optimal dose and dosing frequency of ketamine and highlighted the importance of route of delivery. It also presented data on the use of esketamine in clinical practice and the effectiveness of repeated dosing.<br /><br />The webinar discussed the safety profile and potential risks of ketamine treatment and the importance of monitoring drug dispensing. It highlighted the need for future studies to determine the use of ketamine as monotherapy, its effectiveness in other disorders, and its use in patients with comorbid substance use disorders.<br /><br />The document mentioned the potential effects of ketamine treatment on suicidal ideation and the benefits of augmentation/combination therapies. It also discussed the gender and age factors in ketamine treatment response.<br /><br />The webinar concluded by summarizing key take-home messages, including the evidence of ketamine's rapid antidepressant effects, the importance of monitoring and managing risks, and the need for further research. The document also provided information on the SMI Adviser mobile app, requesting consultations, and other SAMHSA initiatives.<br /><br />The APA and SAMHSA initiative encourages mental health professionals to seek evidence-based practices and stay informed about the latest developments in the field. Upcoming webinars on digital mental health for serious mental illness were also highlighted.

Keywords

Ketamine treatment

Esketamine treatment

American Psychiatric Association

Substance Abuse and Mental Health Services Administration

Depression treatment

Antidepressant effects

Clinical support system for serious mental illness

Funding for mental health initiatives

Optimal dosing strategies

SAMHSA initiatives